Results 81 to 90 of about 18,680 (257)

SCINTIGRAPHY WITH 123I-METAIODBENZILGUANIDINE IN EVALUATION OF SYMPATHETIC INNERVATION OF THE LEFT VENTRICULAR IN PATIENTS WITH CORONARY HEART DISEASE AND ATRIAL FIBRILLATION

Бюллетень сибирской медицины, 2014
The aim of this study was assessment of cardiac sympathetic activity in patients with atrial fibrillation by planar scintigraphy with 123I-metaIodbenzilguanidine (123I-MIBG).Material and Methods.
Yu. B. Lishmanov, S. M. Minin, I. Yu. Yefimova, Yu. V. Saushkina, I. V. Kisteneva   +4 more
doaj   +1 more source

Non‐Functional Paraganglioma of the Urinary Bladder: A Rare Cause of Bladder Tumor

IJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction Paragangliomas of the urinary bladder (PUBs) are rare neuroendocrine tumors, representing less than 0.06% of all bladder neoplasms. While most are functional and associated with catecholamine excess, approximately 15% are non‐functional, often presenting asymptomatically and discovered incidentally.
Matt Wainstein, Vivek Aslot, Faith Dennie, Mark Wainstein, Thenappan Chandrasekar   +4 more
wiley   +1 more source

Rational evaluation of the therapeutic effect and dosimetry of auger electrons for radionuclide therapy in a cell culture model [PDF]

, 2018
学位記番号 ...
Shinohara, Ayaka, シノハラ, アヤカ, 篠原, 彩花   +2 more
core  

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients [PDF]

, 1993
Various tumours, classically specified as either neuroendocrine or non-neuroendocrine, contain high numbers of somatostatin receptors, which enable in vivo localization of the primary tumour and its metastases by scintigraphy with the radiolabelled ...
Bakker, W.H. (Willem), Breeman, W.A.P. (Wouter), Hagen, P.M. (Martin) van, Hofland, L.J. (Leo), Jong, M. (Marcel) de, Kooij, P.P.M. (Peter), Koper, J.W. (Jan), Krenning, E.P. (Eric), Kwekkeboom, D.J. (Dirk Jan), Lamberts, S.W.J. (Steven), Oei, H.Y. (H.), Postema, P.T.E. (Pieter), Reijs, A.E.M. (Ambroos), Reubi, J.-C. (Jean-Claude), Visser, T.J. (Theo)   +14 more
core   +1 more source

Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu, Rou Xue, Xiangwen Luo, Jiangnan Liao, Zongbo Zhang, Jinhai Deng, Teng Liu, Xin Li, Zhe‐Sheng Chen, Mingzhu Yin   +9 more
wiley   +1 more source

A narrative review of 35 years of meta-[131I]iodobenzylguanidine therapy in neuroblastoma

EJC Paediatric Oncology
Neuroblastoma is the most common extracranial solid malignancy of childhood. Approximately half of the patients have high-risk neuroblastoma (HR-NBL), typically presenting as widespread metastatic disease at diagnosis.
Atia Samim, Gitta Bleeker, Kathelijne C.J.M. Kraal, Max M. van Noesel, Bart de Keizer, Godelieve A.M. Tytgat   +5 more
doaj   +1 more source

Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan

Cancer Science, Volume 117, Issue 3, Page 777-786, March 2026.
The safety and antitumor activity of crizotinib at a dose of 165 mg/m2 BID were evaluated in 16 patients with ALK‐positive ALCL in Japan. The most common grade 3 or 4 adverse event was neutropenia. The steady‐state Cmax and AUCtau of crizotinib at 165 mg/m2 BID were higher than expected. The objective response rate was 72.7% (90% CI, 43.6%–92.1%) among
Tetsuya Mori, Akiko Kada, Tomoo Osumi, Daisuke Tomizawa, Yuhki Koga, Reiji Fukano, Kengo Takeuchi, Ukihide Tateishi, Osamu Miyazaki, Ryuta Asada, Akiko M. Saito, Kei Fukuhara, Masahiro Sekimizu   +12 more
wiley   +1 more source

A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group

Cancer, Volume 132, Issue 2, 15 January 2026.
Abstract Background Survival for patients with high‐risk neuroblastoma remains poor despite current‐era multimodality treatment that includes postconsolidation GD2‐directed immunotherapy. Given the promising responses in patients who receive dinutuximab‐based chemoimmunotherapy in the relapsed setting, the Children’s Oncology Group ANBL19P1 study ...
Ami V. Desai, Arlene Naranjo, Brian LaBarre, Lulu Chen, Kelly C. Goldsmith, Meaghan P. Granger, Lisa States, Sean G. Green, Mariel Trunzo, Wendy Fitzgerald, Steven G. DuBois, Rochelle Bagatell, Julie R. Park, Araz Marachelian   +13 more
wiley   +1 more source

Cardiac 123I-mIBG Imaging in Heart Failure [PDF]

, 2022
Derk O. Verschure, Kenichi Nakajima, Hein J. Verberne   +2 more
openalex   +1 more source

Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management

ChemBioChem, Volume 27, Issue 1, January 2026.
Radiopharmaceuticals enable precise cancer diagnosis and targeted therapy by combining radioactive isotopes with carrier molecules. This review summarizes advances from 2014 to 2025, emphasizing probe design, click chemistry, novel targets, and nanodelivery systems.
Mohd Sayeed Shaikh, Rupesh R. Kurhade, Abrar A. M. Siddiqui, Shaikh Shahbaz A. Majeed, Thomas J. Webster, Mohammad Intakhab Alam, Abdul Wasy Zia, Md. Faiyazuddin   +7 more
wiley   +1 more source